Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE:...
Merck Reports 9% Global Sales Growth in Q3 2023, Boosted by Keytruda and Gardasil
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has reported a robust 9%...
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology...
Fujian Cosunter Gains Ethical Approval for Phase IIa Study of GST-HG131 in Hepatitis B
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of ethical approval...
Abbisko Therapeutics Gets NMPA Approval for Phase I Study of ABSK112 in NSCLC
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
NMPA Unveils 73rd Batch of Reference Drugs for Generic Quality Consistency
China’s National Medical Products Administration (NMPA) has released the 73rd batch of reference drugs as...
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a...
Sinotau Pharmaceutical Group Secures Rights to Blue Earth Diagnostics’ Flotufolastat in China
Sinotau Pharmaceutical Group, a Beijing-based nuclear medicine enterprise, has entered into a licensing agreement with...
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a...
Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices
Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured...
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...
Novartis’ Pluvicto Demonstrates Positive Phase III Results in mCRPC Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released encouraging data from a Phase III study...
Life Molecular Imaging and Sinotau Pharmaceutical Secure NMPA Approval for Neuraceq in China
Germany-headquartered Life Molecular Imaging (LMI) and China-based Sinotau Pharmaceutical Group have announced that Neuraceq (florbetaben...
Innovent Biologics’ GFH925 on Track for Priority Review Status for NSCLC Treatment
The Center for Drug Evaluation (CDE) has indicated that Innovent Biologics’s (HKG: 1801) Category 1...
CDE Releases 75th Batch of Generic Reference Preparations with Updated Specifications
The Center for Drug Evaluation (CDE) has announced the release of the 75th batch of...
Zhejiang Jianfeng Receives FDA Approval for JFAN-1001 Clinical Trial in NSCLC
Zhejiang Jianfeng Group Co., Ltd (SHA: 600668), a leading pharmaceutical company based in China, has...
MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the milestone of the first patient...